INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Mar 09, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 150,000 | -- | -- |
| Mar 09, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 150,000 | $30.63 | 713,990 |
| Dec 12, 2019 |
Director, President and CSO
|
Director, President and CSO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 150,000 | $21.25 | 521,876 |
| Dec 12, 2019 |
Director, President and CSO
|
Director, President and CSO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 150,000 | -- | -- |
| Dec 13, 2018 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 150,000 | $16.80 | 150,000 |
| Dec 13, 2018 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 150,000 | -- | 94,048 |
| Dec 13, 2013 |
Director, Pres Regeneron Labs
|
Director, Pres Regeneron Labs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 150,000 | -- | 246,736 |
| Dec 14, 2012 |
Director, EVP CSO Pres Regen Res Labs
|
Director, EVP CSO Pres Regen Res Labs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 150,000 | -- | 245,295 |
| Dec 16, 2011 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 150,000 | -- | 244,048 |
| Dec 16, 2016 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 146,815 | -- | 146,815 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.